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“Adult Cystic Fibrosis Unit, and ‘Department of Respiratory Physiology, Birmingham Heartlands 
Hospital, Bordesley Green East, Birmingham B9 sSS, U.K. 
In patients with cystic fibrosis (CF), nasal intermittent positive pressure ventilation (NIPPV) is currently used as a 
short-term bridge to transplantation but its precise role has yet to be determined. 
Patients were offered a therapeutic trial of NIPPV when candidates for lung transplantation, with respiratory 
failure unresponsive to medical treatment. Twelve patients, six male of mean age of 26 & 1.4 years, had a trial of 
NIPPV. At recruitment the mean percentage predicted forced expired volume in one second (FEV,) was 
151% & 1*2%, arterial carbon dioxide (PaCO,) 8.7 f 0.6 kPa, arterial oxygen (PaO,) with variable FiO, 
7.4 f 0.6 kPa and arterial bicarbonate (HCO;) 40.1 & 1.6 mmol 1~ ‘. 
Ten cases tolerated NIPPV for 1-15 months, mean 5.1 * 1.4 months, with subjective improvement in headache 
and quality of sleep. At 3 months, there was significant improvement in forced vital capacity, PaCO, and arterial 
HCO; and there was a reduction in the number of hospital inpatient days (PcO.05). Subsequently three cases had 
lung transplantation, four died on the active list and three are awaiting organs. Two patients failed to tolerate 
NIPPV owing to abdominal bloating and increasing hypercapnia. 
In conclusion, NIPPV, if tolerated, was a useful adjunct in the treatment of CF patients with hypercapnic 
respiratory failure awaiting transplantation. Further prospective studies are required to determine the optimum time 
to commence NIPPV and to clarify its precise role. 
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Introduction 
The outlook for patients with cystic fibrosis (CF) has 
improved considerably with the refinement of overall 
management and the development of new techniques. The 
major cause of morbidity and mortality remains pulmonary 
disease due to chronic bronchopulmonary infection (1) and 
the majority of patients eventually develop respiratory 
failure despite aggressive treatment with physiotherapy, 
antibiotics, nebulized bronchodilators and DNAse 
(Pulmozymea). 
For a few patients transplantation may be a life-saving 
procedure with current survival of 65% at 3 yr post- 
transplantation (2). Patients are usually considered as the 
forced expired volume in 1 s (FEV,) approaches 30% of 
predicted when the 2 yr mortality is greater than 50% (3). 
Many such patients require long-term oxygen therapy, 
which may be complicated by the development of carbon 
dioxide retention (type II respiratory failure) heralded by a 
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rising serum bicarbonate or the development of morning 
headaches. Nasal intermittent positive pressure ventilation 
(NIPPV) has been used successively in these circumstances 
by Hodson ef al. in the short term for up to 36 days to 
bridge patients to transplantation (4). We describe the use 
of NIPPV in the Birmingham Adult Cystic Fibrosis Unit as 
an adjunct to treatment to optimize oxygenation while 
reducing hypercapnia in 
awaiting transplantation. 
patients with respiratory failure 
Methods 
Patients were recruited from the adult CF clinic comprising 
169 patients. Those selected for a therapeutic trial of 
NIPPV were candidates for lung transplantation who 
despite maximal medical therapy had deteriorated, 
developing symptomatic hypercapnic respiratory failure. 
Each case had hypoxia with PaOz less than 8 kPa which 
could not be corrected without an unacceptable rise 
in PaCO,. 
NIPPV was commenced in hospital as a therapeutic trial 
using a bilevel pressure support system (DP90, Taema, 
U.K. suppliers Deva Medical Electronics Limited, 1 
0 1998 W. B. SAUNDERS COMPANY LTD 
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TABLE 1. Paired data showing mean & SE percentage predicted spirometry, body mass index and arterial blood gases (variable 
fi0,) pre- and post-NIPPV 
Pre-NIPPV 
l-2 
months Pre-NIPPV 3 months Pre-NIPPV 6 months 
Number 10 10 5 5 3 3 
FEV, (“!) 15.4 & 1.3 20.9 iz 3.3* 168 h 2.2 20.6 Z!I 3.4 14.8 f 3.3 17.5 zt 4.6 
FVC (%) 26.5 zt 4.1 31.9 * 4.4* 29.2 f 5.9 35 + 5.5* 23.4 f 5.7 28.8 f 8 
BMI (kg m-‘) 16.8 f 0.5 17.5 f 0.5 17.5 f 1 17.1 f 1 17.7 f 1.2 17.2 f 1.5 
PaCO, (kPa) 8.5 f 0.5 8.5 f 0.6 8.5 f 1.1 I.5 f 0.7” 8.7 f 1.9 6.4 Y!C 1 
PaO, (kPa) 7.3 Lt 0.7 6.9 f 0.5 7.7 zt 1 7.5 f 0.7 8.7 f 1 10 f 1.3 
[HCO, -1 (mm011 - ‘) 40.4 zt 1.7 40.7 * 2.3 39.7 + 2.2 34.1 l 1.5* 37.9 ck 2.8 31.7 zt 3.2 
FEV, (%), percentage predicted forced expired volume in 1 s; FVC (%), percentage predicted forced vital capacity; BMI, body 
mass index; PaCO,, arterial concentration of carbon dioxide; PaO,, arterial concentration of oxygen; [HCO,-1, arterial 
concentration of bicarbonate. 
*P<O.O5 compared with patients pre-NIPPV. 
Chandlers Court, Runcorn, Cheshire, WA7 4UH). The 
pressure settings were adjusted at the bedside with initial 
settings of expiratory positive airway pressure (EPAP) 
2 cmH,O and inspiratory positive airway pressure (IPAP) 
8-12 cmH,O. The respiratory rate was set at 12-18 breaths 
min-’ to match the patient’s own respiration rate. Supple- 
mental oxygen, at between 1 and 4 1 min- ‘, was given via 
the nasal mask. The NIPPV settings were adjusted (in 
conjunction with nasal oxygen) to optimize patient comfort 
and to achieve a PaO, at 8 kPa or above, a PaCO, of less 
than 8 kPa and to alleviate symptomatic hypercapnia. Once 
confident and stabilized on treatment, patients were 
discharged to use NIPPV at home through the night and as 
much during the day as convenient. 
Capillary blood gas samples were measured using a Ciba 
Corning blood gas analyser (model 248, Ciba Corning 
Diagnostics Limited, Halstead, Essex, CO9 2DX). Over- 
night oximetry was carried out using the Pulsox-7 Oximeter 
(Devilbiss Health Care Limited, Airlinks, Middlesex, TW5 
9NR) and overnight transcutaneous carbon dioxide was 
measured using a TINA-TCM3 (Radiometer Limited, 
Manor Court, West Sussex, RHlO 2PY). FEV, and FVC 
were measured using the vitalograph wedge bellows spirom- 
eter (Vitalograph Limited, Buckingham, MK18 1SW). 
Lung function, body weight and capillary gases were 
recorded at commencement of NIPPV, during the period of 
stabilization and subsequently as clinically indicated. 
The number of hospital inpatient days before and after 
commencement of NIPPV was recorded. 
DATA ANALYSIS 
Comparisons of data before and after NIPPV were of 
paired data and all tests of significance were two tailed. 
Wilcoxon’s rank-sum test for non-parametric data was 
performed using the statistical package SPSS@. Statistical 
significance was accepted at the 5% level (PcO.05). Values 
quoted are mean f standard error of the mean. 
Results 
Twelve patients, six males, were recruited with a mean age 
of 26 h 1.4 years. Ten were on the active transplant 
waiting list and two were awaiting initial assessment. At 
recruitment the mean percentage predicted FEV, was 
15.1% * 1.2%, with percentage predicted forced vital capac- 
ity 26.2% f 3.4% and body mass index [weight (kg) divided 
by the square of the height (m)] 16.9 & 0.5 kg m- 2 (normal 
range 19-25 kg me2). PaO, on variable inspired oxygen 
was 7.4 f 0.6 kPa, PaCO, 8.7 f 0.6 kPa and the arterial 
bicarbonate (HC03 -) 40.1 f 1.6 mm01 1 - ‘. 
The data for ten patients who were established on NIPPV 
are presented in Table 1. They were treated from 1 to 15 
months, mean 5.1 & 1.4 months. Most used it for 68 h 
overnight with variable usage by day. Two patients did not 
tolerate NIPPV, one because of abdominal bloating and the 
other as a result of worsening headache and poor sleep 
caused by documented hypercapnia. This was confirmed by 
overnight transcutaneous TINA monitoring in this patient 
which showed PaCO, rising from 12 to 15.5 kPa overnight 
during ventilation. These patients died at 6 and 2 months 
post-assessment respectively. 
Follow-up data on ten patients were available at l-2 
months and on five patients at 3 months. Table 1 shows the 
mean values of lung function, weight and blood gases 
over these time periods with comparison by paired testing. 
At l-2 months there was improvement in FEV, (%) 
(P<O.O5), FVC (%) (PcO.05) and stabilization of the 
blood gases and BMI. By 3 months, there was significant 
improvement in FVC (%), PaCO, and HCO,- (PcO.05) 
with the improvement apparently maintained at 6 months 
in three patients. The trend in HCO,- for individual 
patients is shown in Fig. 1. 
Patients reported subjective improvement in symptoms 
with reduced early-morning headache on wakening, an 
improved quality of sleep and improved well-being during 
the day. Two cases felt that NIPPV aided expectoration and 
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FIG. 1. Arterial bicarbonate since NIPPV was 
commenced. T, patient transplanted; AT, awaiting donor 
organ; D, died. 
nasal irritation, facial pain due to pressure from the mask 
and air leakage but these were generally overcome by 
individual tailoring of the face mask and did not interfere 
with its use. Two patients required a humidifier in the 
NIPPV circuit because of uncomfortable nasal crusting. 
The number of hospital inpatient days before and after 
commencement of NIPPV was recorded. At l-2 months 
following NIPPV there was no significant reduction in the 
number of inpatient days [mean 29.4 * 4.3 and 28.7 & 6.9 
pre- and post-NIPPV respectively (P=O.7)]. By 3 months 
there was a significant reduction in the number of inpatient 
days [mean 41.4 & 13.0 and 23.6 + 11.1 pre- and post- 
NIPPV respectively (P<O.OS)]. A similar trend in reduction 
of inpatient days was seen at 6 months [mean 69.7 * 16.9 
and 45.3 f 19.1 pre- and post-NIPPV respectively (P=O.3)]. 
Three cases have since had lung transplantation at 2, 9 
and 15 months and four have died on the waiting list (at 1, 
2, 5 and 8 months) as organs did not become available in 
time. There are three patients awaiting transplantation who 
are currently continuing NIPPV at home, 2,2 and 5 months 
after its prescription. 
Discussion 
NIPPV has been shown to be of value in chronic respirat- 
ory failure and in the control of nocturnal hypoventilation 
(5,6). Control of nocturnal hypercapnia through nasal 
ventilation may improve sleep quality and result in 
improved neuropsychological performance and quality of 
life (7). Although the outcome of long-term use of NIPPV 
in severe bronchiectasis has been poor (8), Gacouin et al. 
(9) have found that home ventilatory support by NIPPV is 
well tolerated, stabilizes respiratory status and tends to 
reduce the number of days in hospital. 
In patients with cystic fibrosis Hodson et al. used NIPPV 
in the short term, over 3-36 days, to help six patients in 
respiratory failure to reach transplantation (4). Baculard 
et al. used NIPPV in eight CF children with severe chronic 
respiratory failure over a longer term for up to 20 months 
(10). Piper et al. have used it in four adult CF patients with 
hypercapnic respiratory failure for up to 18 months show- 
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ing improved blood gas values, a reduction of dyspnoea, 
subjective improvement in sleep and in the level of daily 
activities (11). 
In the terminal stages of the disease some patients are 
sustained by the realistic hope of lung transplantation but 
many never achieve this and die before organs become 
available. At our centre 34% of patients accepted onto 
transplant lists die awaiting organs (12) and national figures 
are around 29% (13). Symptoms accompanying end-stage 
disease are often distressing owing to hypoxia and hyper- 
capnia. These include anorexia, fatigue, breathlessness, 
headache and poor sleep. During the inevitable waiting 
period for transplantation the main objective is to keep 
patients symptom free and to optimize their physical and 
cardiorespiratory status. 
It is on this basis that we have used prolonged NIPPV up 
to 15 months in CF patients awaiting transplantation. 
Although this was not a controlled trial and the numbers 
were small, we have found that NIPPV, if tolerated, can 
stabilize and in some case improve physiological par- 
ameters, improve symptom control and lead to a reduction 
in the number of hospital inpatient days. This trend con- 
tinued at 6 months but the sample size was small, making 
statistical analysis difficult. 
NIPPV is non-invasive and well tolerated both in hospi- 
tal and at home. Compliance improved with time, indicat- 
ing that the patients were happy with the benefits of the 
procedure. Patients can eat and drink normally and com- 
municate freely and we have found that overnight nasogas- 
tric feeding can continue during NIPPV, despite the 
presence of the face mask. The majority felt improved 
headache and sleep quality which helped their general 
well-being. 
There may naturally be concern about complications 
with NIPPV but we had no cases of pneumothorax and 
found no evidence of sputum retention or increased chest 
infection. There were minor difficulties with nasal dryness, 
which was helped by emollient ointments and humidifica- 
tion, and with leaks around the face mask, which were 
reduced by changing masks. Two patients could not be 
established on NIPPV, one because of abdominal bloating 
which is well recognized but in our experience is rarely 
problematic, even when nasogastric feeding is used con- 
comitantly. The other failed as a result of symptoms of 
worsening hypercapnia. The retention of carbon dioxide 
with pressure cycled machines such as the Bi-PAP@, device 
has previously been reported due to the use of a standard 
exhalation device (Whisper-Swivel) which permits rebreath- 
ing of exhaled carbon dioxide and blunts the effect of the 
Bi-PAP in reducing PaCO, (14). This may be overcome by 
increasing the EPAP setting but in our experience this may 
be poorly tolerated since it interferes with coughing. 
In conclusion we have found NIPPV using a pressure 
support system valuable in the management of CF patients 
with chronic hypoxia and hypercapnia awaiting lung trans- 
plantation. We have seen that NIPPV, if tolerated, can 
stabilize and in some cases improve physiological par- 
ameters, improve symptom control and lead to a reduction 
in the number of hospital inpatient days. Although we have 
used it exclusively in patients awaiting transplantation there 
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may be a role beyond that of a short-term bridge to 
transplantation including the long-term management of 
patients for whom transplantation is not the ultimate goal. 
Further prospective studies are needed to clarify the role of 
NIPPV in both situations and to define the physiological 
parameters which best determine the optimum time to 
commence treatment. 
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